Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, open-label, non-randomized study to characterize the impact of dietary modification on inavolisib associated hyperglycemia and to assess the CYP3A4 induction potential of inavolisib using midazolam as a probe substrate in patients with incurable metastatic solid tumors previously treated with multiple (≥2) lines of therapy

Next Previous
Trial Profile

A Phase I, open-label, non-randomized study to characterize the impact of dietary modification on inavolisib associated hyperglycemia and to assess the CYP3A4 induction potential of inavolisib using midazolam as a probe substrate in patients with incurable metastatic solid tumors previously treated with multiple (≥2) lines of therapy

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inavolisib (Primary) ; Midazolam (Primary)
  • Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Endometrial cancer; Head and neck cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Roche

Most Recent Events

  • 27 Aug 2024 Status changed from active, no longer recruiting to completed.
  • 06 Feb 2024 Status changed from recruiting to active, no longer recruiting.
  • 07 Sep 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top